logo-loader
viewTissue Regenix Group PLC

Tissue Regenix announces changing of the guard as chairman Samuel departs

John Samuel is stepping down after 12 years with the company

Tissue Regenix Group PLC -

Tissue Regenix Group PLC (LON:TRX) has announced that its executive chairman John Samuel is stepping down after 12 years with the company.

Independent director Jonathan Glenn has stepped up to chair the business on an interim basis and in a non-executive role rather than the executive capacity of his predecessor.

In a statement, the company said its board will review the position and further announcements will be made in “due course”.

Randeep Grewal, head of the nominations committee at the regenerative medicines business, thanked Samuel for his “commitment and contribution”, before welcoming Glenn to his new position.

“Jonathan brings with him a deep understanding of the healthcare industry and experience in leading companies through successful growth phases,” Grewal added.

“Jonathan's knowledge and leadership will be increasingly valuable as we look to secure the next stage of our commercial development."

Glenn was formerly chief executive of Consort Medical before its £505mln sale to Recipharm recently.

Quick facts: Tissue Regenix Group PLC

Price: 0.33 GBX

AIM:TRX
Market: AIM
Market Cap: £23.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read